Ibuprofen Bioavailability Study

Healthy Clinical Trial

Official title:

An Open Label, Randomised, Single Dose, Three-way Crossover Study to Compare the Bioavailability of 400 mg Ibuprofen From 2 x 200 mg Ibuprofen Acid Orodispersable Tablets, 2x 200 mg Ibuprofen Acid Tablets and 2 x 342 mg Ibuprofen Lysine Tablets in Fasted Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03180879
• Other study ID #: RB7-UK-1604
• Status: Completed
• Phase: Phase 1
• First received: May 17, 2017
• Last updated: October 4, 2017
• Start date: April 10, 2017
• Est. completion date: June 13, 2017

Study information

• Verified date: April 2017
• Source: Reckitt Benckiser Healthcare (UK) Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This project is the in-house development of a 200 mg ibuprofen acid orodispersable tablet (ODT; meltlet). It is designed to appeal to consumers who want a dosage form that may be taken without water and can be used 'on the go'. Vanquish has an improved organoleptic profile compared to the currently marketed meltet by the Sponsor. ODTs are also considered as a suitable dosage form for children who may be reluctant to swallow tablets. This product has the potential for application in both adults and children due to the convenience of the format and the ease of administration for both groups.

This will be the first pharmacokinetic (PK) assessment of the ibuprofen acid ODT formulation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: June 13, 2017
• Est. primary completion date: June 13, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects who have given written informed consent.

2. Age: = 18 years = 50 years.

3. Body Mass Index (BMI) of = 18.0 and = 30 kg/m2.

4. Healthy as determined by past medical history, physical examination, vital signs, electrocardiogram (ECG), and laboratory tests at screening.

5. Female subject of child bearing potential with a negative pregnancy test at the screening visit and willing to use an effective method of contraception unless of non-childbearing potential or where abstaining from sexual intercourse in line with the preferred and usual lifestyle of the subject from first dose until 3 months after the final dose of study medication.

6. Female subject of non-child bearing potential with negative pregnancy test at the screening visit.

7. Male subject willing to use an effective method of contraception unless anatomically sterile or where abstaining from sexual intercourse in line with the preferred and usual lifestyle of the subject from first dose until 3 months after the final dose of study medication.

Exclusion Criteria:

1. Pregnant or lactating females.

2. A history and/or presence of significant disease of any body system, including significant psychiatric disorders, parasuicide.

3. Any condition that may currently interfere with the absorption, distribution, metabolism or excretion of drugs.

4. A history of allergy or intolerance related to treatment with ibuprofen, aspirin or other non-steriodal anti-inflammatory drugs (NSAIDs), or the excipients of the formulations

5. A history of or active peptic or duodenal ulcers or gastrointestinal bleed or upper gastro-intestinal bleed, or other significant gastro-intestinal disorders.

6. A history of frequent dyspepsia, e.g. heartburn or indigestion.

7. A history of significant and frequent migraine.

8. Current smokers or ex-smokers who have smoked or used nicotine replacement products during the 6 months prior to the first dose of study medication.

9. A history of substance abuse (including alcohol).

10. Consumption of foods or beverages containing caffeine (e.g. coffee, tea, cola and chocolate) above 300 mg caffeine per day, prior to 48 hours of each treatment period. (One cup of coffee equals approximately 50 mg caffeine).

11. Those with positive test for drugs of abuse and alcohol.

12. Ingestion of a prescribed drug at any time in the 14 days before the first dose of study medication (excluding hormonal contraceptives and hormone replacement therapy), or consumption of enzyme inhibitors or inducers 30 days prior to the first dose of study medication (such as barbiturates, carbamazepine, erythromycin, phenytoin, etc.).

13. Ingestion of an over-the-counter preparation within 7 days before the first dose of study medication, including herbal medications, vitamins, fish oil supplements, ibuprofen and other NSAIDs.

14. Those who have consumed grapefruit or grapefruit juice, pumelo or Seville oranges in the 7 days before the first dose of study medication.

15. Donation of blood > 400 mL e.g. to the blood transfusion service in the 12 weeks prior to the first dose of study medication.

16. Known human immune deficiency virus (HIV) positive status, or a positive viral serology test.

17. Topical use of ibuprofen within 7 days before the first dose of study medication.

18. Strenuous physical exercise from 48 hours prior to first dose of study medication.

19. Those previously randomised into this study.

20. Those who are an employee at the study site.

21. Those who are a partner or first degree relative of the Investigator.

22. Participation in a New Chemical Entity clinical study within the previous 3 months or a marketed drug clinical study within the 30 days before the first dose of study medication.

23. Those unable in the opinion of the Investigator to comply fully with the study requirements.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Test - RB ibuprofen acid orodispersible tablets
RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.
• Reference - RB Nurofen ibuprofen acid tablets
RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.
• Comparator - Dolormin ibuprofen lysine tablets
Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.

Locations

Country	Name	City	State
United Kingdom	Simbec Research	Merthyr Tydfil

Sponsors (2)

Lead Sponsor	Collaborator
Reckitt Benckiser Healthcare (UK) Limited	Simbec Research

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Overall proportion of subjects with adverse events (AEs), i.e. the occurrence of one or more AEs per subject		Through study completion - Screening to study follow-up (approx 6 weeks)
Other	Change from baseline in oral temperature.	Measured in degrees Celcius	Through study completion - Screening to study follow-up (approx 6 weeks)
Other	Change from baseline in resting heart rate.	Measured in beats per minute	Through study completion - Screening to study follow-up (approx 6 weeks)
Other	Change from baseline in resting blood pressure..	Measured in mmHg	Through study completion - Screening to study follow-up (approx 6 weeks)
Other	Change from baseline in standard haematology testing.		Through study completion - Screening to study follow-up (approx 6 weeks)
Other	Change from baseline in standard biochemistry testing.		Through study completion - Screening to study follow-up (approx 6 weeks)
Other	Change from baseline in standard urinary testing.		Through study completion - Screening to study follow-up (approx 6 weeks)
Primary	AUC0-t - the area under plasma concentration curve from administration to last quantifiable concentration at time t.	The Test and Reference will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Reference ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:	PK Analysis 0-12hrs
Primary	Cmax - the maximum observed plasma concentration.	The Test and Reference will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Reference ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:	PK Analysis 0-12hrs
Secondary	AUC0-t - the area under plasma concentration curve from administration to last quantifiable concentration at time t.	The Test and Comparator will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:	PK Analysis 0-12hrs
Secondary	Cmax - the maximum observed plasma concentration.	The Test and Comparator will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:	PK Analysis 0-12hrs
Secondary	Kel - Elimination rate constant	Secondary endpoint for Test, Reference and Comparator products	PK Analysis 0-12hrs
Secondary	AUC0-inf - Area under the plasma concentration-time curve from administration to infinity	Secondary endpoint for Test, Reference and Comparator products	PK Analysis 0-12hrs
Secondary	AUCR - Ratio AUC0-t/AUC0-inf	Secondary endpoint for Test, Reference and Comparator products	PK Analysis 0-12hrs
Secondary	Tmax - Time until Cmax is first achieved	Secondary endpoint for Test, Reference and Comparator products	PK Analysis 0-12hrs
Secondary	T1/2 - Plasma concentration (elimination) half-life	Secondary endpoint for Test, Reference and Comparator products	PK Analysis 0-12hrs
Secondary	Cn - The plasma concentration at each planned nominal time point.	Secondary endpoint for Test, Reference and Comparator products	PK Analysis 0-12hrs